(NASDAQ: LPCN) Lipocine's forecast annual revenue growth rate of 5.6% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.72%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.42%.
Lipocine's revenue in 2026 is $1,976,677.On average, 4 Wall Street analysts forecast LPCN's revenue for 2026 to be $4,653,550, with the lowest LPCN revenue forecast at $2,861,477, and the highest LPCN revenue forecast at $6,514,971. On average, 4 Wall Street analysts forecast LPCN's revenue for 2027 to be $8,117,252, with the lowest LPCN revenue forecast at $7,796,066, and the highest LPCN revenue forecast at $8,358,142.
In 2028, LPCN is forecast to generate $18,431,710 in revenue, with the lowest revenue forecast at $17,709,041 and the highest revenue forecast at $18,971,887.